Search

Displaying results 4021 - 4030 of 5900 in total
  1. Drug

    Palifosfamide

    go.drugbank.com/drugs/DB05668
    Investigational

    Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.

  2. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while

  3. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    Picolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. … As a therapeutic agent, the molecule works by binding to zinc finger proteins (ZFPs) in a way that changes their structures and disrupts zinc binding, inhibiting function.

  4. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  5. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.

  6. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

  7. Drug

    Inositol 1,3-bisphosphate

    go.drugbank.com/drugs/DB02942
    Experimental

    It is an experimental compound with no approved therapeutic indications. … The compound corresponds to the soluble headgroup of phosphatidylinositol 3-phosphate (PtdIns(3)P), an endosomal signaling lipid recognized by FYVE domains, and it has been used as a ligand in structural

  8. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind

  9. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  10. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.